Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.

Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean F.H. Investments Inc. violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

FDA Form 483 — F.H. Investments Inc. (November 8, 2024)

FDA inspected F.H. Investments Inc. in Alabama and issued a Form 483 listing 2 inspectional observations following an inspection that concluded 2024-11-08. FDA records classify F.H. Investments Inc. as a outsourcing facility. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	F.H. Investments Inc.
FEI / inspection ID	3010348724
Inspection end date	November 8, 2024
Citation count	2

Citations explained

Observation 1 — Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, Your equipment cleaning process has not been validated to ensure there is no cross-contamination between hazardous and highly-potent hormone active pharmaceutical ingredients (APis), including, testosterone and estradiol. Your firm produces multiple compounded hormone drug products using non- dedicated equipment, including pellet presses that have multiple product contact parts, [(b )(4) Jcontrol hoods, analytical balances, and calipers. Additionally, a non-dedicated vacuum cleaner is used to remove powder drug substance from production equipment and surfaces. For example, A) On October 29, 2024, your operator performed inadequate cleaning of product contact equipment and adjacent areas following production of Testosterone 100 mg pellets, Lot [(b)(4) I, Exp 08/2025. A white residue was observed on the surfaces of the pellet press and the 0C b)(4) J containment hood after post-production cleaning. Your supervising production pharmacist.

Observation 2 — Procedures designed to prevent microbiological contamination of drug products purporting to be

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed. Specifically, Your firm relies on [(b) (4 ) , reported Certificates of[(b) (4) las {> terility as~QJ;a.nce fo r batch release of your compounded hormone drug products purported tci'be·';terile. You firmlacks [ o)(4) I [(6) (4)] sterility testing results in 2024 to validate sterility assurance P.i:?r [ o) (4) Jreported on certificates of[(o) (4) l. *DATES OF INSPECTION EMPlOYEE(S) SI GNATU RE DATE I SSUED SEE REVERSE J ol anna A Nor ton, Investigator 11/8/2024 OF THIS PAGE Joa-.ANomn ~:fl~kb~ A. Ncxlorl4 ~~*:1 1.:1"'2021 X

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

F.H. Investments Inc.’s FDA history

Argus HQ has recorded 1 total FDA action tied to F.H. Investments Inc.: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

Frequently asked questions

Is a Form 483 the same as a Warning Letter?: No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.
Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean F.H. Investments Inc. violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for F.H. Investments Inc.

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2024). FDA Form 483 — F.H. Investments Inc. (November 8, 2024) — 2 Citations. Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-f-h-investments-inc-2024-11-08-3010348724

MLA

"FDA Form 483 — F.H. Investments Inc. (November 8, 2024) — 2 Citations." Argus HQ Research, Digital Empire LLC, 2024, argushq.ai/483/fda-483-f-h-investments-inc-2024-11-08-3010348724.

Chicago

Argus HQ Research. "FDA Form 483 — F.H. Investments Inc. (November 8, 2024) — 2 Citations." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/483/fda-483-f-h-investments-inc-2024-11-08-3010348724.

BibTeX

@misc{argushq_argushq_ai_483_fda_483_f_h_investments_inc_2024_11_08_3010348724_2024,
  title = {FDA Form 483 — F.H. Investments Inc. (November 8, 2024) — 2 Citations},
  author = {{Argus HQ Research}},
  year = {2024},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/483/fda-483-f-h-investments-inc-2024-11-08-3010348724},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗